Comprehensive genomic analyses have been performed for head and neck squamous cell carcinoma (HNSCC), revealing a significant rate of NOTCH1 mutations and identifying NOTCH1 as the second most frequently mutated gene after TP53. Most NOTCH1 mutations are considered inactivating, indicating that NOTCH1 is a tumor suppressor gene. On the other hand, cohorts from Asian populations with HNSCC have shown activating NOTCH1 mutations. HNSCC with NOTCH1 mutations have a worse prognosis than the NOTCH1 wild-type tumors. Additional data on other NOTCH family members have shown that NOTCH promotes HNSCC progression. NOTCH family members, including NOTCH pathway genes, are upregulated in HNSCC compared with normal tissues, and inhibition of the NOTCH pathway decreases cell proliferation and invasion. NOTCH activity in HNSCC is therefore contextual, and NOTCH in HNSCC is considered to have a bimodal role as a tumor suppressor and an oncogene. In this review, recent understandings of NOTCH pathway genes, including NOTCH genes, in HNSCC are described. In addition, the implications of NOTCH pathway alteration for HNSCC-specific NOTCH-targeted cancer therapy are explored.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide (Argiris et al. 2008) , and its prognosis remains poor. HNSCC is considered to arise with the accumulation of genetic and epigenetic alterations. Previously, several mutations that lead to HNSCC development were reported, including TP53, RB1, CDH1, CDKN2A, PTEN, EGFR, and PI3CA mutations (Okami et al. 1998; Papadimitrakopoulou et al. 2001; Murugan et al. 2008; Poeta et al. 2009; Demokan et al. 2012) . To elucidate the gene mutation profile of HNSCC, several comprehensive studies have been performed showing that the NOTCH1 mutation rate is higher than previously considered and provides a new focus on its role in HNSCC (Table 1 ; Agrawal et al. 2011; Stransky et al. 2011) .
In mammals, the NOTCH pathway has 4 receptors (NOTCH1-4) and 5 ligands (JAG1 and 2 and DLL1, 3, and 4). After a ligand binding to a NOTCH receptor, the γ-secretase complex releases the NOTCH intracellular domain (NICD), which moves to the nucleus, resulting in the transcriptional activation of NOTCH target genes, such as HES and HEY (Gordon et al. 2008 ). Each NOTCH receptor has different structures. Different from NOTCH1 and 2, NOTCH3 and 4 have a shortened extracellular domain and lack the intracellular transcriptional activating domain. Only NOTCH4 lacks the NOTCH cytokine response region (Fig. 1) .
However, the complete diversity of NOTCH receptor functions and relationships with the downstream target genes in HNSCC is not well understood. Several clinical trials have examined the effect of NOTCH inhibitors on solid tumors. However, few studies have defined effects on each NOTCH receptor and its pathway genes. In this review, we introduce recent HNSCC studies addressing NOTCH pathway genes. Finally, we discuss the current understanding regarding anti-NOTCH therapy.
NOTCH1
In several cancers, including prostate (Zayzafoon et al. 2004) , pancreas (Miyamoto et al. 2003) , breast (Reedijk et al. 2005) , and lung (Westhoff et al. 2009 ), NOTCH1 is reported to have oncogenic functions and promote cancer growth. In HNSCC, several studies have shown that HNSCC has significantly higher NOTCH1 expression than normal tissue (Table 2 ; Leethanakul et al. 2000; Hijioka et al. 2010; Zhang et al. 2011; Yoshida et al. 2013; Wirth et al. 2016) . NOTCH1 expression is correlated with both T stage and the clinical stage in oral squamous cell carcinoma (OSCC; Yoshida et al. 2013) . Its expression is also significantly related to neck lymph node metastasis and the depth of invasion in tongue cancer patients (Joo et al. 2009; Zhang et al. 2011) . Gu et al. (2010) found that NOTCH1 760297J DRXXX10.1177/0022034518760297Journal of Dental ResearchNOTCH Pathway in HNSCC research-article2018 1 Moores Cancer Center, University of California, La Jolla, CA, USA expression was significantly related to cisplatin resistance and that a gamma secretase inhibitor, which is a NOTCH inhibitor, showed a synergistic anticancer effect with cisplatin. Furthermore, NOTCH1 is related to maintenance of a cancer stem cell (CSC) phenotype. Zhao et al. (2016) showed that NOTCH1 inhibition reduces the HNSCC CSC fraction. We also examined the correlation between NOTCH1 and its downstream genes using an updated the Cancer Genome Atlas (TCGA) data set excluding NOTCH mutant samples (HNSCC: 447, normal: 46 samples). Although the correlation coefficients are lower than 0.2, NOTCH1 shows a weakly positive correlation with the NOTCH downstream gene activation in HES1 and HEY1. NOTCH1 expression also shows a significantly positive correlation with BCL-2 expression (Table 3) . In these contexts, NOTCH1 is considered to be upregulated in HNSCC and is closely related to its progression.
In 2011, Agrawal et al. and Stransky et al. exam- ined the whole exons of 120 and 74 HNSCC tumors, respectively (Table 1) . Along with well-known mutations, both research groups reported novel mutations in NOTCH1. Mutations of NOTCH1 were found in 10% to 15% of HNSCC tumors, making NOTCH1 is the second most frequently mutated gene after TP53. They also revealed that NOTCH1 mutations were inactivating and concluded that NOTCH1 acted as a tumor suppressor in HNSCC (Agrawal et al. 2011; Stransky et al. 2011 ). In the other squamous cell carcinoma (SCC) studies for NOTCH mutations, 81% of cutaneous SCC samples were reported to have at least 1 NOTCH1 or NOTCH2 mutation. In addition, 12.5% of lung SCC samples have NOTCH1 or NOTCH2 mutation that is inactivating . Gao et al. (2014) showed mutation rates of NOTCH1 (13%), NOTCH2 (4%), and NOTCH3 (6%) using exome sequencing of 113 pairs of tumor and normal DNA samples collected from esophageal SCC. Genomic comprehensive analysis for esophageal SCC in 144 patients revealed that 19% and 8% of tumors have NOTCH1 and NOTCH3 mutations, respectively (Sawada et al. 2016) . These NOTCH mutation rates in lung and esophageal SCC are similar to those in HNSCC (Table 1) .
The TCGA project was constructed to identify the genes and signal pathways that can be used as potential targets in cancer treatment (de Castro and Negrao 2014) . In HNSCC, comprehensive analysis of somatic genome alterations was performed using this data set showing several gene mutation rates such as those for TP53 (72%), CDKN2A (22%), and PI3KCA (21%). Furthermore, NOTCH1 mutations were identified in approximately 20% (Cancer Genome Atlas 2015) . After this study, the sample number was increased to 500. Fukusumi et al. (2017) showed that the NOTCH1 mutation rate was 11% using this recent TCGA data set. This mutation rate is the highest among NOTCH receptors (Table 1 ; Fukusumi et al. 2017) . Pickering et al. (2013) and Gaykalova et al. (2014) used their 25.3%). The NOTCH1 mutation domain and type were similar to Chinese ones, indicating this mutation was activating (Ock et al. 2016) . Vettore et al. (2015) also examined HNSCC in a Singapore cohort and revealed that NOTCH pathway genes' mutation in OSCC is associated with a significantly worse DFS. However, this study showed a lower NOTCH mutation rate (NOTCH1: 5%, NOTCH2: 1.6%, and NOTCH3: 5%) compared with other Asian studies (Vettore et al. 2015) .
To reconcile the apparent discrepancy between NOTCH inactivating mutations and NOTCH pathway upregulation and activation in HNSCC, investigators have performed comprehensive analyses integrating mutation and network activation and expression data. Sun et al. (2014) found that 10.8% of NOTCH1 mutations were identified in HNSCC tumors and performed a comprehensive analysis of NOTCH signaling in their cohort. They also compared the activation of NOTCH by the downstream genes HES1/HEY1 between HNSCC tumors with and without NOTCH1 mutations and found significantly lower HES1/HEY1 expression in HNSCC tumors with NOTCH1 mutation than in those with NOTCH1 wild type. Furthermore, these NOTCH1 mutant tumors have similar HES1/HEY1 expression to normal tissues, consistent with the loss-of-function of NOTCH1 mutations described above. On the other hand, they found that 30.3% of NOTCH1 wild-type tumors exhibited HES1/HEY1 overexpression, indicating NOTCH pathway activation. In the TCGA cohort, they observed that decreased expression of HES1 showed borderline significance in the NOTCH1 mutant versus wild-type HNSCC tumors, whereas increased expression of HEY1 showed a statistically significant difference . Rettig et al. (2015) stained NICD in HNSCC tumors. NICD expression was significantly associated with the NOTCH1 mutation status. NOTCH1-mutated tumors most commonly exhibited negative staining. There were no significant differences in recurrence, invasion, or clinical stages between NOTCH1 wild-type and mutant patients (Rettig et al. 2015) . These results indicate that inactivating NOTCH mutations do not necessarily correlate with a poorer clinical prognosis.
In summary, NOTCH1 likely plays a bimodal role in HNSCC, with inactivating mutations indicating a tumor suppressor role and activating mutations and upregulation consistent with an oncogenic role.
NOTCH2
NOTCH2 is known to play an important role in hepatocellular and esophageal carcinoma. NOTCH2 affects proliferation, cell cycle, chemoresistance, sphere formation ability, and tumorigenicity in hepatocellular carcinoma cells (Wu et al. 2016) . NOTCH2 is also an independent prognostic factor for OS and progression-free survival in esophageal SCC (Wang et al. 2016) .
In HNSCC, higher NOTCH2 expression was detected compared with normal tissues (Leethanakul et al. 2000; Zou et al. 2016 ). The NOTCH2 expression was increased in HNSCC with lymph node metastasis compared with that without metastasis. NOTCH2 also affects cell growth and apoptosis, and knockdown of NOTCH2 inhibited the migration and invasion abilities and decreased the expression levels of its downstream genes such as c-MYC and BCL-2 (Zou et al. 2016) . In contrast, TCGA analysis showed a significantly decreased NOTCH2 mRNA expression in HNSCC samples compared with that in normal samples (Fig. 2) , and no significantly positive correlation was found between the expression of NOTCH2 and NOTCH downstream genes (Table 3) .
NOTCH3
NOTCH3 alteration is also reported to correlate with several cancers. A large meta-analysis was performed on 3,663 nonsmall-cell lung carcinomas showing that NOTCH3 expression, as well as NOTCH1 expression, was significantly correlated Figure 2 . The Cancer Genome Atlas (TCGA) data set analysis of NOTCH receptors between head and neck squamous cell carcinoma (HNSCC) and normal samples. The mRNA expression of NOTCH1-4 is compared between HNSCC (n = 447) and normal samples (n = 46) using the TCGA data set. Seventy-three HNSCC samples with NOTCH mutation are excluded. The ratio is calculated by dividing the mRNA expression of the tumor samples by that of the normal samples. Whiskers indicate the minimum and maximum values. The P value is calculated using Student's t test. with a worse OS (Yuan et al. 2015) . In glioma, NOTCH3 expression was also associated with a significantly worse prognosis (Alqudah et al. 2013) . NOTCH3 also plays a critical role in the development of prostate cancer as well as the prostate gland (Villaronga et al. 2008 ). In HNSCC, Stransky et al. (2011) showed that the NOTCH3 mutation rate was 4%, and these mutations were inactive (Table 1) . Sun et al. (2014) examined NOTCH-related gene expression arrays using their cohort. The mRNA expression of NOTCH3 was significantly higher in primary HNSCC tumors than in normal mucosa. Similarly, significantly increased expression of NOTCH3 was found in HNSCC tumors using the TCGA HNSCC data set . We examined the updated TCGA data set and show a significantly positive correlation between NOTCH3 and HEY1 expression (Table 3) . However, moderate but not significantly increased NOTCH3 expression in HNSCC was noted using this TCGA data set (Fig. 2) . Using HNSCC cells, NOTCH3 inhibition decreases cell proliferation, chemoresistance, sphere formation ability, xenograft tumor volume, and the expression of NOTCH downstream genes such as HEY1, BCL-2, c-MYC, and CCND1 (Man et al. 2012) . Tongue cancers had significantly higher NOTCH3 expression than normal tongue tissue Zhang et al. 2013b) , and NOTCH3 expression showed a significant correlation with its clinical stage (Zhang et al. 2013b ). Kayamori et al. (2016) noted that NOTCH3 did not affect OSCC cell proliferation. However, they focused on cancerassociated fibroblasts (CAFs) in OSCC and indicated that NOTCH3 in CAFs promoted angiogenesis, and immunohistochemical study of 93 OSCC cases indicated that NOTCH3 expression in CAFs was significantly correlated with tumor size. Furthermore, OSCC with NOTCH3 (+) CAFs showed a significantly worse OS than that with NOTCH3 (-) CAFs (Kayamori et al. 2016) . These data are consistent with a possible bimodal oncogenic and tumor suppressor role for NOTCH3, similar to that of NOTCH1. Ha et al. (2003) used their 26-patient cohort and showed that only NOTCH4 expression in HNSCC was significantly increased compared with that in normal mucosa among NOTCH receptors. Using comparative genomic hybridization (CGH) analysis, DLL1 and NOTCH4 were upregulated in OSCC compared with that in normal tissue, whereas NOTCH1, 2, and 3 and HES1 were expressed at lower levels (Snijders et al. 2005) . The chromosomal region of NOTCH4 was shown to amplify in OSCC using CGH analysis (Table 2 ; Lunde et al. 2014 ). Similar to these results, our TCGA analysis also showed that NOTCH4 expression shows the highest ratio among NOTCH receptors in HNSCC compared with that in normal tissues, although the difference was not statistically significant (Fig. 2) . The mutation rate of NOTCH4 was the lowest among NOTCH receptors (Table 1) .
NOTCH4
Breast cancer cells were shown to induce epithelialmesenchymal transition (EMT) via NOTCH4 (Lombardo et al. 2014) . NOTCH4 is an EMT trigger and promotes the metastasis of melanoma cells (Lin et al. 2016) . In these backgrounds, Fukusumi et al. (2107) examined NOTCH4 function and demonstrated that NOTCH4 was significantly related to HNSCC cell proliferation, chemotherapy resistance, cell cycle, apoptosis inhibition, and EMT using the TCGA data set and in vitro experiments. Clinically, NOTCH4 expression is also significantly related to T stage, clinical stage, and perineural invasion (Mk et al. 2016) .
As shown in Table 3 , NOTCH4 expression is significantly related to its downstream genes such as HEY1 and BCL2. Fukusumi et al. (2014) indicated that NOTCH4 promotes EMT through HEY1, as described below. NOTCH4 expression was also reported to be increased in breast CSC (Simões Bruno et al. 2015) . In HNSCC, CD10 (Fukusumi et al. 2014) , CD44 (Prince et al. 2007) , and ALDH1 (Chen et al. 2009 ) are defined as CSC markers. Thus, the expression levels of these markers were compared using the TCGA data set. Significant differences in ALDH1 were noted between the NOTCH4/HEY1 high and low groups. Si-NOTCH4 and si-HEY1 cells also showed significantly increased ALDH1 expression. From these results, the authors suggested that ALDH1 could regulate the NOTCH4-HEY1 pathway (Fukusumi et al. 2017) .
NOTCH Pathway Genes
Similar to NOTCH receptors, NOTCH ligands also relate to HNSCC progression. JAG1 and 2 expressions in HNSCC are significantly higher than that in normal mucosa Sun et al. 2014 ). JAG1 expression is related to poor prognosis (Lin et al. 2010 ) and lymph node metastasis . JAG1 regulates the differentiation, proliferation, and angiogenesis in HNSCC (Zeng et al. 2005; Zhang et al. 2013c) . Recently, several studies have shown that DLL4 can regulate tumor angiogenesis (Noguera-Troise et al. 2006; Ridgway et al. 2006) . In HNSCC, DLL4 expression has a significantly positive correlation with expression of vascular endothelial growth factor. Moreover, DLL4 expression is independently associated with poor prognosis and significantly elevated in distant metastases compared with primary HNSCC tumors (Zhang et al. 2013a) .
After ligand binding to a NOTCH receptor, NICD activates NOTCH downstream genes. Rettig et al. (2015) performed immunohistochemical staining for NICD in the tonsils and HNSCC samples. All tonsil specimens expressed NICD. In the tumor samples, 81% stained positive. Among tumor samples, most of the NOTCH1 wild-type samples had positive NICD staining (89%). Half of the mutated NOTCH1 samples had negative staining. The authors also found that negative NICD staining was significantly associated with poor differentiation. Furthermore, NICD positive staining was significantly negatively associated with lymph node metastasis (Rettig et al. 2015) . However, Gokulan and Halagowder (2014) showed that the normal oral epithelium predominantly exhibited negative staining for NICD, the expression of NICD was gradually increased from dysplasia to carcinoma, and NICD staining was higher in stage III to IV cases than in stage I to II cases. Furthermore, a significant correlation was found between NICD expression and lymph node metastasis of OSCC. In this study, NICD expression in NOTCH wild-type HNSCC is consistent with a more aggressive phenotype characterized by and EMT phenotype (Gokulan and Halagowder 2014) .
HES, HEY, CCND1, MYC, BCL-2, and p21 are among a large number of NOTCH target genes. Among these genes, the roles of HES and HEY in HNSCC are not well understood. The most prominent targets of the NOTCH pathway are the HES and HEY families (Kalaitzidis and Armstrong 2011; Sethi et al. 2011 ). Thus, several recent studies have focused on these functions in HNSCC. To elucidate the HNSCC-specific correlation of NOTCH pathway genes, we examined the correlation between each NOTCH receptor and its associated NOTCH downstream genes using the updated TCGA data set. Several significantly positive correlations were found, such as NOTCH1-BCL2, NOTCH3-HEY1, NOTCH4-HEY1, and NOTCH4-BCL2 (Table 3) . Among them, NOTCH3, 4 and HEY1 have been shown to have a mutual relationship described below (Man et al. 2012; Sun et al. 2014; Fukusumi et al. 2017) . Sun et al. (2014) found that both HES1 and HEY1 mRNA expressions in HNSCC were significantly higher than in normal mucosa. In addition, 14% and 25% of HNSCC tumors showed overexpression of HES1 and HEY1 compared with that in normal mucosa. In total, 31.8% HNSCC tumors showed overexpression of HES1 and/or HEY1. In their microarray, HES1 and HEY1 were also overexpressed in tumor samples; either HES1 or HEY1 was overexpressed in 26.8% of HNSCC samples, a finding similar to that in the previous expression array data (31.8%; Sun et al. 2014) . Wirth et al. (2016) also showed elevated expression of HES1 and HEY1 in HNSCC compared with normal tissues.
HES1 expression is upregulated in OSCC lesions compared with that in dysplastic lesions. HES1 promoted sphere formation ability, indicating that HES1 activates the CSC phenotype (Lee et al. 2012) . Another study showed that the expression of HES1 was higher in stage III to IV cases than in stage I to II OSCC cases. A higher expression of HES1 was also found in lymph node metastasis-positive cases than in negative cases. HES1-positive OSCC showed significantly worse DFS than negative cases (Gokulan and Halagowder 2014) .
TCGA mRNA sequence analysis showed that HEY1 expression exhibited a significant positive correlation with all NOTCH receptors but that HES1 did not show a similar association with NOTCH receptor expression. Among these receptors, NOTCH4 exhibited the most significant correlation to HEY1 expression. HEY1 expression in HNSCC was significantly increased, approximately twice as high as that in normal samples, and in vitro experiments revealed the same results (Fukusumi et al. 2017) . In general, HEY1 is known to regulate EMT. HEY1 expression in HNSCC was also related to an EMT phenotype as determined by gene expression in both the TCGA data set analysis and in vitro experiments (Fischer et al. 2007; Luna-Zurita et al. 2010; Fukusumi et al. 2017) . Man et al. (2012) confirmed that HEY1 expression of HNSCC cells was significantly higher than that of normal epithelial cells. In the studies noted above, there are consistent data demonstrating that the NOTCH4-HEY1 pathway of HNSCC can be specifically up-regulated and promote EMT.
Anti-NOTCH Therapy
The NOTCH pathway is an attractive cancer therapeutic target, and its inhibition has been shown to decrease cell proliferation and invasion (Yao et al. 2007 ). Many types of NOTCH inhibitors exist, including monoclonal antibodies, RNAi, receptor decoys, and glycosylation/protease inhibitors (Ran et al. 2017) . Among them, γ-secretase inhibitors (GSIs) are the most used inhibitors for several cancer studies and clinical trials (Strosberg et al. 2012; De Jesus-Acosta et al. 2014) . DAPT used as a GSI enhanced the radiation-induced apoptosis of HNSCC cells (Yu et al. 2011) . Furthermore, GSI can inhibit sphere formation ability and decrease the CSC fractions (Upadhyay et al. 2016) . The combined therapy of DAPT and conventional drugs improved its anticancer effect synergistically . These results are consistent with NOTCH being related to CSC. Thus, anti-NOTCH therapy can be efficient for HNSCC CSC that is considered chemoresistant and radioresistant, albeit in experimental systems.
However, GSIs cannot inhibit specific, individual NOTCH receptors. Ran et al. (2017) performed NOTCH substance activity assays using various GSIs (BMS-906024, PF-3084014, RO4929097, semagacestat, MK-0752, and DAPT) and showed that each GSI had different effects against each NOTCH receptor. Only BMS-906024 inhibited all NOTCH substrates nearly equivalently (Ran et al. 2017) . NOTCH signaling is necessary for tissue homeostasis. Thus, nonspecific inhibition by GSIs can induce severe side effects such as gastrointestinal toxicity, diarrhea, hepatotoxicity, and nephrotoxicity (Searfoss et al. 2003; van Es et al. 2005; Garber 2007; Wu et al. 2010) .
To avoid this nonspecific inhibition, anti-NOTCH1, 2, and 3 antibodies have been developed, although a functional anti-NOTCH4 antibody has not been developed yet, as NOTCH4 lacks an extracellular component for ligand binding that is a potential target for an inactivating antibody (Fig. 1) . The anti-NOTCH1 antibody significantly decreased the growth of mouse xenograft colon cancer cells without weight loss and severe side effects for normal goblet cells . Huntzicker et al. (2015) showed that the anti-NOTCH2 antibody reduced mouse liver tumors, but the anti-NOTCH3 antibody did not decrease the tumor burden. Anti-DLL4 antibody and nanoparticles have been examined in terms of a potential anticancer effect for HNSCC cells. They indicate anti-DLL4 therapy enhances radiation response and decreases angiogenesis (Liu et al. , 2015 .
These studies indicate the importance of specific NOTCH target cancer therapy, and further analysis of the HNSCCspecific NOTCH pathway and establishment of NOTCH subtype-specific therapies may offer the opportunity for therapeutic effect while minimizing side effects.
Discussion
Most studies in this review reveal NOTCH pathway is upregulated in HNSCC, and NOTCH expression shows significant correlations with clinical stage (Joo et al. 2009; Zhang et al. 2011) . NOTCH is also related to EMT Fukusumi et al. 2017) , and EMT has been related to the therapeutic resistance, invasion, and metastasis of cancers (Bao et al. 2006; Li et al. 2008) . Thus, the NOTCH pathway can play an important role in HNSCC development, and anti-NOTCH therapy can be attractive.
However, as described above, NOTCH1 is considered to play a bimodal role as a tumor suppressor and an oncogene unlike other highly mutated genes in HNSCC such as TP53 and PTEN, which are well-established tumor suppressor genes. Of note, the NOTCH1 mutations show divergence between Caucasian and Asian patient studies. There are no significant differences in recurrence, invasion, and clinical stages between NOTCH1 wild-type and mutant patients (Agrawal et al. 2011; Stransky et al. 2011; Rettig et al. 2015) . On the other hand, several Asian studies have indicated that NOTCH1 mutation is activate type, and HNSCC with NOTCH1 mutation has a worse prognosis than NOTCH1 wild-type tumors (Song et al. 2014; Vettore et al. 2015) . It will be important to examine whether the difference of NOTCH1 mutation types are related to germ line genetic differences or exposures. The authors in Asian studies noted the higher alcohol concentration in Chinese liquor as a potential differential factor (Song et al. 2014; Izumchenko et al. 2015) .
Human papilloma virus (HPV)-related HNSCC is considered to have different gene expression and pathways compared with HPV-negative HNSCC (Suárez et al. 2016) . In HPVpositive cervical cancer, NOTCH1 expression is significantly downregulated, and NOTCH3 expression was significantly upregulated compared with normal cervix tissue (Tripathi et al. 2014) . HPV E6 protein decreases NOTCH1 expression (Kranjec et al. 2017) . In HNSCC, NOTCH1 is more mutated in HPV-negative samples than in HPV-positive samples (Rettig et al. 2015) . Higher NOTCH1 expression in HPV-positive HNSCC is shown compared with HPV-negative HNSCC (Kaka et al. 2017) . However, there is no comprehensive analysis for each NOTCH pathway gene alterations comparing HPV-positive and -negative HNSCC and no definitive study defining whether HPV E6/7 affects the NOTCH pathway in HNSCC.
There are several challenges that can be addressed for anti-NOTCH therapy in HNSCC. However, the NOTCH pathway is also important for oral normal tissue homeostasis as well as other organs (Harada et al. 1999 ). Thus, HNSCC-specific NOTCH pathway therapy would likely need to be tailored to specific NOTCH isoforms, to avoid systemic and gastrointestinal toxicities. Implicit in this concept is the need to characterize the contextual action of the NOTCH pathway in individual patients, such that NOTCH-targeted therapy is used exclusively for NOTCH pathway-activated tumors. Despite the challenges of NOTCH pathway-directed therapies, the high proportion of HNSCC with NOTCH pathway activation and the key role that NOTCH plays in development of this cancer indicate that NOTCH-based therapy has significant potential affect HNSCC outcomes.
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